Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Zillow Group Inc Class A (ZG) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Zillow Group (ZG) trades at $28.85, up 0.56% on the day, amid a bearish technical signal but with improving fundamentals. The company reported a return to profitability in 2025 with net income of $23 million (source: company earnings, 2025), and revenue growth is projected to continue. Recent news highlights AI integration in real estate and shifting housing market dynamics. Analyst consensus is a 'Hold' with a $48.60 price target, suggesting significant potential upside from current levels.

The outlook is cautiously optimistic. The primary opportunity lies in the substantial gap between the current price and the analyst target, coupled with revenue growth and a strategic pivot. Key risks include persistent housing market affordability headwinds, competitive pressures, and the stock's high P/E ratio of 127.3, which demands sustained earnings growth to justify.